Is Routine Pathology Evaluation of Tissue Removed for Fertility Preservation Necessary?

• Published in: Journal of pediatric surgery 2024-11, Vol.59 (11), p.161632, Article 161632
• Main Authors: McElhinney, Kathryn L., Orr, Sierra, Gelarden, Ian A., Laronda, Monica M., Rowell, Erin E.
• Format: Article
• Language: English
• Subjects: Adolescent; Biopsy - methods; Child; Child, Preschool; Cryopreservation - methods; Female; Fertility preservation; Fertility Preservation - methods; Gonadotoxic therapy; Humans; Male; Ovarian tissue cryopreservation; Ovary - pathology; Ovary - surgery; Pediatric oncofertility; Retrospective Studies; Testicular tissue cryopreservation; Testis - pathology
• ISSN: 0022-3468; 1531-5037; 1531-5037
• DOI: 10.1016/j.jpedsurg.2024.07.017

For all fertility preservation (FP) cases at our institution, a biopsy is performed for routine pathology from all gonadal tissue removed. This is not standard at all centers. We reviewed our experience with biopsy for pathological evaluation of ovarian and testicular specimens in FP cases to determine clinical utility. The medical records of individuals who underwent ovarian tissue cryopreservation (OTC) or testicular tissue cryopreservation (TTC) between 2011 and 2023 were retrospectively reviewed under an IRB-approved study at a free-standing tertiary care children's hospital. Patient demographics, diagnosis, operative characteristics, and pathology results were collected. One-hundred and eighty-three patients underwent OTC, and 134 patients underwent TTC. All patients had their gonadal tissue biopsied for routine pathology. Malignancy was identified in the biopsies of 4 OTC patients (2.2%) and 2 TTC patients (1.5%). Two OTC patients (1.1%) and 2 TTC patients (1.5%) did not have germ cells identified in their biopsy. All OTC and TTC patients and families elected to continue storing tissue for FP after discussion of pathology findings. Pathology results provide another data point to help inform patients and their families when making decisions on ovarian or testicular tissue storage and on how tissue may be utilized in the future to restore fertility and/or hormones. There is a low rate of identifying malignancy in gonadal tissue biopsies taken from FP specimens even in patients with known malignancy. However, when malignancy was identified, it could be unexpected and alter the diagnosis and treatment plan significantly for patients. IV. •Ovarian and testicular tissue removed for fertility preservation can contain cancer cells.•There is a low rate of identifying malignancy in gonadal tissue biopsies taken from FP specimen. Biopsies provided information about patient disease and provided vital information for future decisions about tissue reimplantation.